SUSETTE DEAN: Open Payments
NPI 1821742537 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,256 in 55 payments from 18 companies in 2025. Trend: 2023 $330 · 2024 $187 · 2025 $3,256
Food & beverage: $2,414Consulting: $820Travel & lodging: $22
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 8 | $1,147 |
| Madrigal Pharmaceuticals | 19 | $542 |
| Regeneron Healthcare Solutions, Inc. | 4 | $243 |
| Novo Nordisk Inc | 2 | $208 |
| Janssen Biotech, Inc. | 3 | $173 |
| Ardelyx, Inc. | 4 | $153 |
| Janssen Scientific Affairs, LLC | 1 | $139 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $118 |
| Intercept Pharmaceuticals, Inc. | 1 | $116 |
| ABBVIE INC. | 1 | $115 |
Products named: Livdelzi, REZDIFFRA, DUPIXENT, TREMFYA, IBSRELA, Ozempic, XIFAXAN, OCALIVA.
Industry payments across NY — which companies pay providers there.
